



CITADEL
DISCOVERY

PRESS RELEASE

For More Information Contact:

Eric Sigel

Harvard Square, One Mifflin Place

Suite 400

Cambridge, MA 02138

eric@citadeldiscovery.io

For Immediate Release

Citadel Discovery Talks AI and Drug Discovery at Ai4 2023

Cambridge, MA –Citadel Discovery is proud to announce that we will be a sponsor and featured presenter at Ai4 2023. Ai4 2023 brings together business leaders and data practitioners to facilitate the responsible adoption of artificial intelligence and machine learning technology.

Citadel is presenting at this year's conference on our advanced use of AI and ML for drug discovery. Citadel was launched in 2021 with the purpose of broadening access to the data and technology that will drive the future of pharma research streamlining and lowering the costs of drug discovery and biological research.

Our platform provides an alternative framework for early drug discovery by leveraging our access to DNA-Encoded Libraries (DELs) to rapidly and cost-effectively generate readouts on tens of millions of small molecules that are used to train custom, project-specific AI models. Citadel has recently demonstrated successful prediction by these models, identifying significant numbers of molecules with known, potent activity to an internal target out of collections in the millions of compounds. We have now moved to validate model predictivity with prospective studies and are applying the approach to several partnered targets.

Citadel has recently signed its eighth contract in early July with projects ranging from single-target DEL-ML (DNA-Encoded Library Machine Learning) multi-target DEL-ML, with partners that include startups, mid-sized Biotech, and top ten Pharma.

"DEL-ML continues to show increasing promise across a wide range of efforts across the industry with reported successes on new targets and applications building each quarter. We are thrilled to be working with our partners to realize Citadel Discovery's mission to broaden the impact and opportunity of this exciting technology and to enable them to expand and accelerate their AI for drug discovery digital transformation," said Citadel CEO Eric Sigel.



CITADEL
DISCOVERY

At their current pace, Sigel says that he expects contracts to exceed ten by the end of summer, adding, “The costs of drug discovery continue to rise, with current estimates exceeding \$2 Billion. Not to mention that bringing a drug successfully through all clinical trial phases takes, on average, 10-12 years in research and development. Artificial intelligence and machine learning in drug discovery hold the key to reducing these costs and timelines.”

Ai4 2023 will be held Monday, 8/7, through Wednesday, 8/9, 2023, at MGM Grand, Las Vegas. [Click here](#) for registration and more information.

###

Citadel Discovery is dedicated to leveraging AI and MI for the purpose of democratizing access to the data and technology that will drive the future of biological exploration, drug discovery, and health technologies. If you would like to benefit from our expertise in these areas or if you have further questions on the content of this article, please do not hesitate to [contact us](#).